MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Do the JADE101 Phase 1 Interim Results Reveal

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Do SSTK's Q1 2026 Results Reveal About Its Core Business

2 months ago

What Do the SYNAPSE-CMT Phase 2a Results Mean for NMD Pharma

1 months ago

What Do KNOT Offshore Partners' Q1 2026 Results Reveal

1 months ago

What Do Summit Therapeutics' Q4 Results Reveal About Its Financial Health

5 months ago

ALT and the Rise of Dual Agonists Targeting Liver Disease

Altimmune's pemvidutide faces pivotal 2026 trials in MASH and alcohol-related liver disease, testing its dual-agonist approach against single-pathway rivals.

ALT

Stock News•1 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Pfizer's monthly GLP-1 RA berobenatide showed robust Phase 2b efficacy and favorable tolerability at ADA, supporting Phase 3 dose selection and monthly dosing potential.

PFE

Stock News•1 months ago

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Fractyl Health participants retained ~78% of GLP-1 induced total body weight loss one year after a single Revita procedure and subsequent drug discontinuation. These open-label results suggest the tre...

GLP

Stock News•1 months ago

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Jade Biosciences (JBIO) reported positive interim results from its Phase I healthy volunteer study of JADE101. The company is now advancing development plans for the candidate, marking a key milestone...

JBIO